Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Deferred Taxes (2021 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Deferred Taxes for 5 consecutive years, with -$1.7 million as the latest value for Q4 2025.

  • Quarterly Deferred Taxes fell 104.25% to -$1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $40.8 million through Dec 2025, down 40.08% year-over-year, with the annual reading at $40.8 million for FY2025, 40.08% down from the prior year.
  • Deferred Taxes hit -$1.7 million in Q4 2025 for Ironwood Pharmaceuticals, down from $27.8 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $41.1 million in Q4 2024 to a low of -$1.7 million in Q4 2025.
  • Historically, Deferred Taxes has averaged $14.0 million across 5 years, with a median of $14.2 million in 2023.
  • Biggest five-year swings in Deferred Taxes: surged 941.33% in 2022 and later crashed 104.25% in 2025.
  • Year by year, Deferred Taxes stood at $1.9 million in 2021, then soared by 941.33% to $20.1 million in 2022, then skyrocketed by 55.6% to $31.3 million in 2023, then skyrocketed by 31.23% to $41.1 million in 2024, then crashed by 104.25% to -$1.7 million in 2025.
  • Business Quant data shows Deferred Taxes for IRWD at -$1.7 million in Q4 2025, $27.8 million in Q3 2025, and $14.1 million in Q2 2025.